CSPC Pharmaceutical Group Ltd. has announced that its recombinant fully human anti-βKlotho monoclonal antibody drug, JMT202, has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. This drug, an FGFR1c/βKlotho receptor agonist, is designed to regulate glycolipid metabolism and has potential applications in treating metabolism-related diseases such as dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and obesity. The clinical trial will focus on hypertriglyceridemia $(HTG.UK)$. JMT202 has previously obtained approval from the National Medical Products Administration of China and is undergoing trials in China. Preclinical studies have shown that the drug has a favorable safety profile and can significantly reduce triglyceride levels, suggesting promising clinical development potential.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.